The pituitary adenylate cyclase–activating polypeptide (PACAP) is a neuropeptide of the vasoactive intestinal peptide/secretin/glucagon superfamily. Studies in two related patients with a partial trisomy 18p revealed three copies of the PACAP gene and elevated PACAP concentrations in plasma. The patients suffer from severe mental retardation and have a bleeding tendency with mild thrombocytopenia, and their fibroblasts show increased PACAP mRNA levels. The PACAP receptor (vasoactive intestinal peptide/pituitary adenylate cyclase–activating peptide receptor 1 [VPAC1]) in platelets and fibroblasts is coupled to adenylyl cyclase activation. Accordingly, we found increased basal cAMP levels in patients' platelets and fibroblasts, providing a basis for the reduced platelet aggregation in these patients. Megakaryocyte-specific transgenic overexpression of PACAP in mice correspondingly increased PACAP release from platelets, reduced platelet activation, and prolonged the tail bleeding time. In contrast, the PACAP antagonist PACAP(6-38) or a monoclonal PACAP antibody enhanced the collagen-induced aggregation of normal human platelets, and in PACAP knockout mice, an increased platelet sensitivity toward collagen was found. Thus, we found that PACAP modulates platelet function and demonstrated what we believe to be the first hemostatic defect associated with PACAP overexpression; our study suggests the therapeutic potential to manage arterial thrombosis or bleeding by administration of PACAP mimetics or inhibitors, respectively.
The pituitary adenylate cyclase–activating polypeptide (PACAP) is a neuropeptide of the vasoactive intestinal peptide/secretin/glucagon superfamily. Studies in two related patients with a partial trisomy 18p revealed three copies of the PACAP gene and elevated PACAP concentrations in plasma. The patients suffer from severe mental retardation and have a bleeding tendency with mild thrombocytopenia, and their fibroblasts show increased PACAP mRNA levels. The PACAP receptor (vasoactive intestinal peptide/pituitary adenylate cyclase–activating peptide receptor 1 [VPAC1]) in platelets and fibroblasts is coupled to adenylyl cyclase activation. Accordingly, we found increased basal cAMP levels in patients’ platelets and fibroblasts, providing a basis for the reduced platelet aggregation in these patients. Megakaryocyte-specific transgenic overexpression of PACAP in mice correspondingly increased PACAP release from platelets, reduced platelet activation, and prolonged the tail bleeding time. In contrast, the PACAP antagonist PACAP(6-38) or a monoclonal PACAP antibody enhanced the collagen-induced aggregation of normal human platelets, and in PACAP knockout mice, an increased platelet sensitivity toward collagen was found. Thus, we found that PACAP modulates platelet function and demonstrated what we believe to be the first hemostatic defect associated with PACAP overexpression; our study suggests the therapeutic potential to manage arterial thrombosis or bleeding by administration of PACAP mimetics or inhibitors, respectively.

Introduction

The pituitary adenylate cyclase–activating polypeptide (PACAP) was first isolated from ovine hypothalamic extracts on the basis of its ability to stimulate cAMP formation in rat anterior pituitary cells (1, 2). This neuropeptide bears partial sequence homology with vasoactive intestinal peptide (VIP), growth hormone–releasing hormone, secretin, and glucagon. Its role in biology seems crucial, since the sequence of PACAP is highly conserved during the evolution from protochordates to mammals. Like other hypophysiotropic neurohormones, PACAP is contained in extrahypothalamic neurons as well as in numerous peripheral tissues. Consistent with its widespread distribution, PACAP has been found to exert pleiotropic effects including modulation of neurotransmitter release, vasodilation, bronchodilation, activation of intestinal motility, increase of insulin and histamine secretion, and stimulation of cell multiplication and/or differentiation (2). PACAP therefore is believed to act as a hormone, a neurohormone, a neurotransmitter, and a trophic factor in different tissues.

The human PACAP gene is located on chromosome 18p11.32 and encodes a 176–amino acid prepro–protein, which comprises a 24–amino acid signal peptide (3). In all mammalian species studied so far, the sequences of the active PACAP peptides PACAP(1-38) and its derived form PACAP(1-27) are located in the C-terminal domain of the precursor. Both forms were found to be equipotent in receptor-binding and adenylyl cyclase assays (4). The active peptide PACAP(1-38) is mainly expressed in testis and brain, but this peptide can cross the blood–brain barrier and is stably transported in plasma through coupling to ceruloplasmin (5–7).

PACAP(1-38) and PACAP(1-27) are ligands for three G protein–coupled receptors: the PACAP-specific PAC1 receptor, which is coupled to several transduction systems and mainly expressed in the CNS, and the PACAP/VIP-indifferent VIP/G protein–coupled receptors, which are primarily coupled to adenylyl cyclase and widely distributed in peripheral tissues (8–11). The wide distribution of PACAP receptors has led to an explosion of studies aimed at determining the pharmacological effects and biological functions of this peptide. PACAP has presently been investigated in many organs and tissues, such as endocrine glands, CNS, respiratory system, cardiovascular system, and gastrointestinal tract (2). Extensive studies have also been performed on its function in the immune system, but no data are currently available to support a function for PACAP in hemostasis. Only one study reports that PACAP inhibits the cyclooxygenase pathway of rat platelets via a specific PACAP receptor–activated, cAMP-dependent pathway (12).

We previously have described several unrelated patients with a novel genetic defect and inducible hyperactivity of the adenylyl cyclase–stimulatory G protein (Gs) (13, 14). These patients have an increased Ivy
bleeding time and other abnormalities, including a variable degree of mental retardation and mild skeletal malformations. Modest stimulation via different Gs-coupled platelet receptors in these patients triggers strong and rapid adenylyl cyclase activation, thereby antagonizing platelet activation. Because we found that hyperfunction of the Gsα pathway could lead to a bleeding phenotype (13), we have investigated how a partial trisomy 18p, which results in overexpression of the Gs agonist PACAP and is also associated with a pronounced bleeding phenotype, affects platelet function. We found that PACAP is a natural regulator of platelet activation. This rather unexpected role of PACAP in hemostasis was further confirmed in both PACAP knockout mice and mice with megakaryocyte-specific overexpression of PACAP.

Methods

Generation and genotyping of mice with megakaryocyte-specific overexpression of PACAP and Southern blot analysis. The murine GPIIb promoter (extending from +23 to 508 relative to the initiation start site) was excised from the mGPIIb-pGL3 plasmid by digestion with KpnI and BamHI and inserted into the KpnI-BamHI-digested PACAP-pcDNA3.1 vector (Invitrogen Corp., Carlsbad, California, USA) in front of the mouse PACAP gene (15). The mouse PACAP gene was amplified from brain cDNA with primers mPACAP1R 5′-GTAGCGCGCTCGAGGATCTGCTACAAGTATGC-3′ and mPACAP1F 5′-GTGATGCCGAATTCAGTTCAAGGTCTGGCTAG-3′, sequenced, and cloned into the EcoRI-XhoI site of the pcDNA3.1 vector. The 2.2-kb KpnI-DraIII fragment (GPIIb-PACAP) was excised and purified for zygote injection. The GPIIb promoter has been successfully used to restrict transgene expression to the megakaryocytic cell lineage of mice (16). Transgenic PACAP-overexpressing mice were generated by zygote injection into the Friend leukemia virus, strain B (FVB) background according to previously published procedures (17, 18). Transgenic offspring were identified by PCR screening using genomic DNA extracted from tail samples. The following primer pair was used: mGPIIb1F 5′-TGGCCACATCACAGCTTGAAG-3′ and mPACAP1R. Southern blot analysis was performed to identify founders; 40 genomic offspring were identified by PCR screening using genomic DNA of mice anesthetized by intraperitoneal injection of 60 mg/kg sodium pentobarbital. The genotype was confirmed by PCR using primers mGPIIb1F and mGPIIb1R. The GPIIb promoter has been successfully used to restrict transgene expression to the megakaryocytic cell lineage of mice (16).

Production of polyclonal and monoclonal antibodies. Primary anti-PACAP mAb (PP1A4) and anti-PACAP, anti-regulator of G protein signaling-2 (anti-RGS2), and anti-VPAC1 polyclonal antibodies were produced in our laboratory by injection of mice and rabbits, respectively, with recombinant fusion proteins consisting of the PACAP(1-38) peptide sequence, the complete VPAC1 sequence, or the N-terminal part of the recombinant fusion proteins consisting of the PACAP(1-38) peptide sequence, the complete VPAC1 sequence, or the N-terminal part of the RGS2 sequence, each coupled to glutathione-S-transferase. These recombinant fusion proteins were expressed in Escherichia coli and purified by affinity chromatography on immobilized glutathione (Amer sham Biosciences AB, Uppsala, Sweden). The primary antibodies were purified on protein A-Sepharose beads (Amer sham Biosciences AB) and controlled for their reactivity toward recombinant PACAP(1-38), VPAC1, or RGS2 by immunoblot.

Human platelet aggregation. Blood was anticoagulated with 3.8% (wt/vol) trisodium citrate (9:1), and platelet-rich plasma (PRP), obtained by centrifugation (150 g for 15 minutes), was reconstituted (3,000 g for 15 minutes) to produce platelet-poor plasma (PPP-trisodium citrate). Finally, the platelet count in the PRP was adjusted to 250 × 10⁶ platelets per liter with PPP. Platelet aggregation was performed on two dual-channel Chrono-Log aggregometers (Chrono-Log Corp., Havertown, Pennsylvania, USA) by simultaneous recording of four tracings. Aggregation-inhibition studies were done as described previously (13, 14) and involved dose-response curves to the stable prostacyclin analogue and Gs agonist iloprost (Ilomédine; 0–5 ng/ml; Schering AG, Berlin, Germany), which was added to PRP 1 minute before induction of aggregation by Horm collagen (2 µg/ml; Nycomed Arzneimittel, Munich, Germany). The IC₅₀ value was calculated after curve fitting using the software InStat 2.03 (GraphPad Software Inc., San Diego, California, USA). The IC₅₀ values ± SD were compared with those for the same Gs agonist on control platelets, studied simultaneously.

In vivo effect of anti-PACAP antibodies on platelet aggregation in mice. FVB mice were injected three times subcutaneously with 200 µg of an anti-PACAP, an anti-RGS2, or an anti-VPAC1 polyclonal antibody or four times with 50 µg of an anti-PACAP mAb (PP1A4) with an interval of 3 days between injections. At day 14 after the first injection, whole blood from the inferior vena cava of mice anesthetized by intraperitoneal injection of 60 mg/kg sodium pentobarbital was drawn into 20 µg/ml hirudin. A platelet count was performed on the venous blood sample using the CELL-DYN 1300 (Abbott Laboratories, Abbott Park, Illinois, USA). Blood was centrifuged at 100 g for 10 minutes, allowing separation of PRP, and P was obtained by centrifugation of the remaining blood at 2,000 g for 10 minutes. PRP and P were pooled from five mice in each group. Platelet aggregation was measured as described above with the platelet count adjusted to 250 × 10⁶ platelets per liter. All animal experiments were approved by the institutional review board and were conducted according to NIH guidelines for animal experiments.

Bleeding time and platelet aggregation in PACAP-overexpressing mice. The bleeding time was determined as described previously (19). Eight- to 15-week-old mice were bled under sodium pentobarbital anesthesia from the retroorbital plexus. Mouse blood was collected in a saline solution containing 20 µg/ml hirudin. Preparation of PRP and aggregation were done as described above.

Immunoblot detection of PACAP in washed platelet releasates. Blood was collected into trisodium citrate and centrifuged at 200 g for 15 minutes at room temperature to yield PRP. PRP from five mice was pooled. Then, 0.1 µl of acid citrate dextrose (ACD; 2.5% trisodium citrate, 1.5% citric acid, 2% D-glucose) was added to the PRP, and platelets were purified from PRP by centrifugation at 700 g for 15 minutes at room temperature. The platelet pellet was washed and resuspended in 250 µl HEPES/Tyrode buffer (10 mM HEPES, 137 mM NaCl, 2.68 mM KCl, 0.42 mM NaH₂PO₄, 1.7 mM MgCl₂, 11.9 mM NaHCO₃, pH 7.4) containing 5 mM D-glucose at 100 × 10⁶ platelets per liter. Platelets were activated with 10 µg/ml Hrom collagen and pelleted. The washed platelet-releasate proteins were resolved by SDS-PAGE and transferred to Hybond ECL-nitrocellulose membranes (Amersham Biosciences AB). Blots were revealed with a monoclonal antiserum against PACAP (PP1A4) and stained with Western blotting ECL detection reagent (Amersham Biosciences AB).

Platelet aggregation in PACAP knockout mice. Generation of PACAP knockout mice has been previously described (20). Blood from the heart of mice anesthetized by intraperitoneal injection of 60 mg/kg sodium pentobarbital was drawn into 0.1 M citrate, and PRP and P were pooled from three mice. Platelet aggregation was performed on an MCM Hema Tracer 313M model PAM-12C (MC Medical Inc., Tokyo, Japan) using Hrom collagen at indicated concentrations.

cAMP detection in human and mouse platelets. We incubated citrated PRP with iloprost (1 ng/ml), arrested the reaction at different time points by adding 12% trichloroacetic acid, and measured human platelet cAMP using a cAMP enzyme immunoassay (Amersham Biosciences AB). Basal cAMP levels in human platelets were measured in the presence of the phosphodiesterase inhibitor 3-isobutyl
I-methylxanthine (IBMX; 100 µM final concentration). The accumulation of cAMP in mouse platelets was measured in the absence of IBMX, using a [125I]cAMP RIA kit (Amersham Biosciences AB) as previously described (21).

**Human skin fibroblasts and cAMP detection.** Skin fibroblasts were obtained via punch biopsy from the volar side of the upper arm. Fibroblasts were cultured in DMEM/H12 (Invitrogen Corp.) supplemented with 10% FBS and antibiotics (Invitrogen Corp.), at 37°C in a 5% CO2 humidified incubator. Only fibroblasts of low passage number (between 6 and 12) were used for DNA and RNA extraction and for cAMP measurements. Cells were grown to 100% confluence and then incubated in serum-free medium for 24 hours before cAMP analysis. Fibroblasts were plated in duplicate, one plate being used for the assay, the other for cell counting; the obtained cAMP levels were thus adjusted for the cell number. Patient or control fibroblasts were stimulated with the Gs agonist isoproterenol (Calbiochem-Novabiochem Corp., San Diego, California, USA) at 1 µM final concentration. The accumulation of cAMP was measured in the absence of IBMX, using a [125I]cAMP RIA kit (Amersham Biosciences AB) as previously described (21).

**Results**

**Patient descriptions.** We describe a family characterized by an unbalanced segregation of the reciprocal translocation t(18;20) (p21;p13), in which several members manifest severe mental retardation (Figure 1). The propositus (VI:1) is a 23-year-old man with multiple neurological problems (epilepsy, hypotonia, convulsions, mental retardation, tremor, psychotic behavior, hyperactive behavior), gastrointestinal problems (diarrhea, vomiting), and endocrinological problems (hypoplasia of the pituitary gland, hypogonadotropic hypogonadism). In addition, he presented on different occasions with a moderate thrombocytopenia, the platelet count being 70 × 10^9 to 90 × 10^9 platelets per liter. He has a severe bleeding problem with repetitive epistaxis, even leading to hypovolemic shock, and a markedly prolonged Ivy bleeding time (>15 minutes), though coagulation studies are normal. He has a decreased platelet secretion of ATP and β-thromboglobulin despite platelet electron microscopy showing a normal amount of dense and α granules. His karyotype shows a partial trisomy 18p and monosomy 20p.

His brother (VI:2), father (V:2), and maternal grandmother (IV:6) are phenotypically normal, have no bleeding problems, and have a normal karyotype. In contrast, his mother (V:3) and paternal grandfather (IV:5) have no obvious neurological abnormalities but borderline IQs. They carry the balanced translocation t(18;20) (p21;p13). They have no obvious bleeding problem and have a normal platelet count. The propositus’s 47-year-old uncle (V:4) also suffers from severe mental retardation, hypogonadism, pronounced recurrent epistaxis, and cryptorchidism. Furthermore, he frequently has gastric bleeding, and his platelet count is around 150 × 10^9 platelets per liter. He also has a partial trisomy 18p and monosomy 20p.

### Table 1: Platelet aggregation

<table>
<thead>
<tr>
<th></th>
<th>IC_{50} ± SD</th>
<th>EC_{50} ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV:6</td>
<td>0.96 ± 0.002</td>
<td>0.25 ± 0.012</td>
</tr>
<tr>
<td>IV:5</td>
<td>0.40 ± 0.003</td>
<td>0.74 ± 0.013</td>
</tr>
<tr>
<td>IV:3</td>
<td>0.47 ± 0.003</td>
<td>0.75 ± 0.006</td>
</tr>
<tr>
<td>IV:4</td>
<td>0.27 ± 0.005</td>
<td>1.08 ± 0.006</td>
</tr>
<tr>
<td>VI:1</td>
<td>0.34 ± 0.004</td>
<td>1.03 ± 0.008</td>
</tr>
<tr>
<td>Controls</td>
<td>1.04 ± 0.39</td>
<td>0.22 ± 0.6 (n = 10)</td>
</tr>
</tbody>
</table>

*IC_{50} ± SD for indicated individuals, and the mean IC_{50} value for iloprost in the platelet aggregation inhibition test with 2 µg/ml collagen in 22 controls, were calculated. A significantly lower IC_{50} value (F_p < 0.03 or D_P ≤ 0.0076) indicates Gs hyperfunction. The right column illustrates the decreased response to collagen of IV:5 and V:3 (F_p ≤ 0.0003) and of IV:4 and VI:1 (F_P ≤ 0.0001) compared with ten controls. Effector concentration (EC_{50}) is expressed as the collagen concentration that induces aggregation with an amplitude that is 50% that of maximal aggregation.*
monosomy 20p. Patients and/or their legal representatives consented to the determination of platelet and fibroblast Gs activity and the molecular analysis.

Adenylyl cyclase activity in platelets and fibroblasts. The propositus (VI:1) has a disturbed platelet function evidenced by a gain-of-Gs activity measured in the platelet aggregation inhibition test, which is seemingly similar to what we previously described for patients with an inducible Gs hyperfunction syndrome (13, 14). Platelets from the patients (VI:1 and V:4) with the partial trisomy 18p and monosomy 20p had a significantly increased sensitivity toward the Gs agonist iloprost (Table 1), while platelets from the family members (IV:5 and V:3) with the balanced translocation showed a moderately increased sensitivity. The IC50 value for member IV:6 with the normal karyotype is within the range of the IC50 values from 22 unrelated controls. An important difference between patients from this family and the patients with the inducible Gs hyperfunction we reported previously is their decreased sensitivity toward different platelet agonists (collagen, ADP, and U46619). The collagen aggregation was further studied in more detail in all family members and different unrelated controls. The collagen concentration needed to obtain 50% aggregation of platelets from V:4 and VI:1 is significantly higher than for platelets from controls or the normal member IV:6 (Table 1). The reactivity of platelets from IV:5 and V:3 toward collagen is again mildly affected. This suggested that in the platelets of the propositus (VI:1), adenylyl cyclase is already activated under basal conditions. In addition to an increased cAMP response to iloprost, patient VI:1 indeed showed higher basal cAMP levels (Figure 2A). We also performed cAMP measurements in fibroblasts from VI:1 and found a similarly increased basal and stimulated cAMP response (Figure 2B). Interestingly, measurement of the adenylyl cyclase activity in fibroblasts from an unrelated patient with a complete trisomy 18 showed similarly increased basal and stimulated cAMP levels (Figure 2B).

PACAP(1-38) mRNA and protein overexpression. A genetic defect in one of the Gsα isoforms could be excluded (13, 24, 25). Patient VI:1 has a normal Gsα and XLαs protein expression level, and the coding sequence for the Gsα gene and XL-exon I are completely normal (data not shown). Since this patient has a partial trisomy 18p and monosomy 20p, these chromosomes were screened for candidate genes. The gene for PACAP (ADCYAPI) is located on chromosome 18p11.32 and is a possible candidate since its active peptide PACAP(1-38) stimulates Gs-coupled receptors and thereby activates adenylyl cyclase. FISH analysis with YAC clone YAC 841C3 (23), which contains ADCYAPI, showed that the translocation results in three copies of the gene in patients VI:1 and V:4 (Figure 3).
Human skin fibroblasts express PACAP(1-38) and the PACAP type 1 receptor (26). PACAP(1-38) mRNA was overexpressed in fibroblasts from patient VI:1 compared with the control. RT-PCR was performed on two separate fibroblast samples, and β-actin is the internal control. (B) PACAP mRNA detection in fibroblasts, megakaryocytic cell lines DAMI, MEG-01, and K562, and platelets was performed by RT-PCR. (C) Immunoblot analysis of the VPAC1 receptor (58 kDa) in platelets from two unrelated controls and patient VI:1. (D) PACAP detections by ELISA in plasma from citrate (left panel) or ACD (right panel) blood from VI:1 (squares) and V:4 (triangles) or IV:5 (circles) and V:3 (filled diamonds) versus a citrated plasma pool (asterisks) or IV:6 (open diamonds). (E) The left panel shows the dose-dependent stimulation by PACAP(6-38) of the collagen-induced (0.2 µg/ml) aggregation of normal human platelets; representative tracings of five separate experiments are shown. The right panel illustrates the effect of PACAP(6-38) on collagen-induced (2 µg/ml) platelet aggregation in patient VI:1. Coll, collagen.
The PACAP antagonist also induced a partial but consistent improvement of the collagen-induced platelet aggregation in the patient (Figure 4E).

**Role for PACAP in platelet function, studied in mice.** Different mouse models were studied to further evaluate the role of circulating PACAP(1-38) as a physiological inhibitor of platelet function. In mice the levels of PACAP, detected by ELISA, were higher than in human plasma; moreover, we found that PACAP levels in serum were 1.5-fold higher than in plasma, which suggested that platelets might contribute significantly to circulating PACAP(1-38) levels (Figure 5A).

To examine the effect of increased platelet PACAP levels on platelet function, transgenic mice with a PACAP overexpression in the megakaryocyte lineage were developed. The mouse PACAP gene was placed behind the platelet GPIIb promoter to drive megakaryocyte-specific expression (16). Southern blotting identified three transgenic founders with germ-line transmission of the transgene, and the founder line Tg9, with high levels of PACAP platelet expression, was selected and characterized in detail (Figure 5B). Both platelet and circulating PACAP levels were increased in the PACAP-overexpressing mice as detected by immunoblot analysis of PACAP in washed platelet releasates (Figure 5C) and ELISA detection of PACAP in serum and plasma (Figure 5D), respectively. Moreover, as for the patients, the transgenic PACAP-overexpressing mice presented an increased bleeding time and showed an increased sensitivity toward collagen-induced aggregation (Figure 5E). Mouse platelets incubated with anti-PACAP antibodies (10 ng/ml) showed an enhanced response to collagen (data not shown), and mice subcutaneously injected with anti-PACAP or anti-VPAC1 antibodies showed an enhanced response to ADP or collagen 7 days after the last injection (Figure 6, A and B). Platelets isolated from PACAP-deficient mice consistently had mildly (not significantly) decreased basal cAMP levels (wild-type mice, 133.2 ± 15.2 pmol cAMP per 10⁹ platelets; PACAP-deficient mice, 103.4 ± 6.39 pmol cAMP per 10⁹ platelets) and also showed an increased sensitivity toward collagen stimulation during aggregation studies compared with platelets from control mice (Figure 6C).

**Discussion**

We report the hematological consequences of PACAP overexpression, as a consequence of a partial trisomy 18p. This neuropeptide and its receptors are widely distributed, and therefore PACAP exerts pleiotropic physiological functions. Indeed, PACAP has been implicated in a wide range of biological processes, including reproductive, development, growth, cardiovascular, respiratory, and digestive functions, immune responses, and circadian rhythms (2). Our two patients with increased PACAP plasma levels, an increased bleeding tendency, and a mild thrombocytopenia also suffer from several neurological, endocrinological, and gastrointestinal defects. Further studies are needed to define whether these three latter defects are a consequence of the PACAP overexpression and reflect the pathophysiological activity of this peptide or are the result of other genes involved in the unbalanced translocation. However, we show in these patients, and also in both PACAP knockout and PACAP-overexpressing mice, that circulating PACAP modulates normal platelet function, and we
have identified this Gs agonist as a new physiological inhibitor of platelet aggregation.

Many pharmacological responses to PACAP infusion and its effects on the CNS, the pituitary gland, and the gastrointestinal system have already been studied in detail. PACAP is thought to act within the hypothalamus as a neurotransmitter or neuromodulator to regulate the secretion of neurohypophysial and hypophysiotropic neuroehromones. Intracerebroventricular injection of PACAP results in a dose-dependent elevation of plasma vasopressin and release of oxytocin (27); injection of PACAP in the medial basal hypothalamus suppresses luteinizing hormone release (28), while central administration of PACAP produces an increase in somatostatin, gonadotropin-releasing hormone, and corticotropin-releasing factor (29). PACAP can stimulate cAMP formation in pituitary cells and releases growth hormone, follicle-stimulating hormone, and adrenocorticotropic hormone (30, 31).

The effects of PACAP on the gastrointestinal system relate to the secretory activity of exocrine and endocrine cells; in addition, PACAP induces a relaxation of gastric smooth muscles, causing a decrease of gastric motility (32, 33). PACAP also plays a role in the cardiovascular system by regulating blood pressure (34), but hematomical changes upon PACAP administration to animals have not been documented.

PACAP-deficient mice manifest an altered psychomotor behavior, defects in female reproduction, a dysfunction of lipid and carbohydrate metabolism, and early death (20, 35–37). Knockout models for the PACAP receptors PAC1 and VPAC2 show altered emotional behavior, decreased female fertility and/or growth retardation, an increased basal metabolic rate, a role of PACAP in the relaxation in the proximal colon, and a disturbed circadian function (38–43). None of these studies reports on a potential role for PACAP in hematology. Platelets, however, only express the PACAP receptor VPAC1, for which a knockout model does not yet exist. In this study we show, for the first time to our knowledge, that platelets from PACAP-deficient mice have an increased sensitivity toward collagen stimulation. In contrast, platelets from mice with megakaryocyte-specific overexpression of PACAP have a decreased sensitivity toward collagen. PACAP mRNA is detected in platelets, and, in the mouse, serum PACAP levels are higher than in plasma. Furthermore, PACAP could be detected by immunoblotting in washed platelet releasates, suggesting that PACAP may be released from platelets following activation. This could then constitute an autocrine pathway, which would dampen the extent of activation following platelet stimulation.

In the present family, we observed an unbalanced segregation of the reciprocal translocation t(18;20) (p21;p13) with a variable clinical phenotype. The propositus, VI:1, and his uncle, V:4, have a partial trisomy 18p and monosomy 20p associated with the full-blown clinical picture of severe mental retardation and a severe bleeding tendency, while the propositus’s mother, V:3, and maternal grandfather, IV:5, who have a balanced translocation, have borderline IQs with no clinical bleeding problems despite a moderately abnormal platelet function. In accordance with the clinical observations, patients VI:1 and V:4 have very high PACAP plasma levels, increased basal cAMP levels, and a platelet Gs hyperfunction, while these parameters are only mildly disturbed in family members V:3 and IV:5. It is difficult to presume what causes these increased PACAP expression levels. If an additional copy of the PACAP gene on chromosome 18p in patients VI:1 and V:4 results in PACAP overexpression, it is hard to understand why family members with the balanced translocation have moderately raised PACAP and a disturbed platelet function. Further studies are needed to evaluate the role of potential regulatory elements located in the translocation region of chromosome 18p or to exclude the possibility that family members V:3 and IV:5 have an unusual chromosomal mosaicism that would account for their intermediate phenotype. Such a hidden mosaicism for a supernumerary derivative chromosome in a carrier of a familial reciprocal translocation was previously described in a patient with mental retardation and congenital malformations (44). The fact that PACAP expression in the trisomy 18 fibroblasts was elevated supports a PACAP gene-dosage effect.

By this genetic study in patients with a pronounced bleeding tendency, we identified PACAP as a new physiological inhibitor of platelet activation, a conclusion experimentally validated via the use of different mouse models. This knowledge may lead to new modalities in the prevention and treatment of thrombosis and bleeding, based on the administration of PACAP or its antagonists.
This work was supported by research grants G.0371.01 and KAN2000-1523100 from the Fonds voor Wetenschappelijk Onderzoek - Vlaanderen (FWO-Vlaanderen) and OT/00/25 and GOA/2004/09 from Katholieke Universiteit Leuven. K. Freson is a postdoctoral fellow of the FWO, and C. Van Geet holds a clinical-fundamental research mandate from the FWO. We gratefully acknowledge Hisashi Kato for his valuable advice and support. This research was supported, in part, by a Grant-in-Aid for Scientific Research and Exploratory Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan to A. Baba and H. Hashimoto, and by grants from AstraZeneca Pharmaceuticals LP and the Naito Foundation to H. Hashimoto.

Received for publication June 20, 2003, and accepted in revised form January 13, 2004.

Address correspondence to: Kathleen Freson, Center for Molecular and Vascular Biology, University of Leuven, Herestraat 49, B-3000 Leuven, Belgium. Phone: 32-16-345775; Fax: 32-16-345990; E-mail: kathleen.freson@med.kuleuven.ac.be.